Active Stocks
Mon Apr 15 2024 15:59:36
  1. Tata Steel share price
  2. 160.90 -1.59%
  1. ITC share price
  2. 425.90 -0.98%
  1. State Bank Of India share price
  2. 757.75 -1.17%
  1. ICICI Bank share price
  2. 1,078.80 -2.30%
  1. NTPC share price
  2. 361.35 -0.08%
Business News/ News / India/  India-based Hetero's Covid-19 oral drug Nirmacom gets WHO backing
BackBack

India-based Hetero's Covid-19 oral drug Nirmacom gets WHO backing

India's Pharmaceutical company Hetero received WHO's backing for its generic version of Covid-19 oral antiviral treatment candidate 'Nirmatrelvir'

Hetero's 'Nirmacom' (Nirmatrelvir) is co-packaged with ritonavir tablets. (Representative image)Premium
Hetero's 'Nirmacom' (Nirmatrelvir) is co-packaged with ritonavir tablets. (Representative image)

India's Pharmaceutical company Hetero said it has received World Health Organization (WHO) Prequalification of medicines program (WHO PQ) approval for its generic version of Covid-19 oral antiviral treatment candidate 'Nirmatrelvir'.

It said that it is the first prequalification for a generic version of Pfizer's Covid oral antiviral drug 'PAXLOVID', which the WHO called, the best therapeutic choice for high-risk patients to date.

Hetero's 'Nirmacom' (Nirmatrelvir), a generic version of Pfizer's Covid-19 oral antiviral drug 'PAXLOVID' is co-packaged with ritonavir tablets.

WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate Covid-19 patients at the highest risk of hospital admissions, such as unvaccinated, aged, or immunosuppressed patients.

The combi pack, launched by Hetero as Nirmacom, will contain nirmatrelvir 150 mg (2 tablets) and ritonavir 100mg (1 tablet). It is available by prescription only and should be initiated as soon as possible after diagnosis of coronavirus and within five days of symptom onset. Nirmacom will be manufactured at Hetero's facilities in India.

Dr Vamsi Krishna Bandi, Managing Director, Hetero Group of Companies, said: "WHO Prequalification for Nirmacom is a significant milestone in the fight against Covid as it allows us to expand access to this important innovative antiretroviral drug to people in need. We are committed to making Nirmacom available faster at affordable prices across 95 LMICs including India."

Hetero entered into a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) for manufacturing and sale of a generic version of Pfizer's Covid-19 oral antiviral treatment candidate nirmatrelvir, which is co-packaged with ritonavir (nirmatrelvir; ritonavir), in LMICs (low- and middle-income countries).

Hetero said it has already received Emergency Use Authorisation (EUA) approval from the Drugs Controller General of India (DCGI) to manufacture and market NIRMACOM. The treatment bundles two nirmatrelvir pills and one ritonavir pill and will be manufactured at Hetero's plants in India.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed ā€“ it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 28 Dec 2022, 06:56 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App